Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in Virginia

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Awareness

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context has traditionally emphasized broad wellness principles, disease awareness, and the importance of informed patient-provider communication. Within this framework, discussions of pharmaceutical interventions have focused on therapeutic benefits and standard risk disclosures, often framed within the language of clinical efficacy and population-level health outcomes. As the informational landscape evolves, a more granular focus has emerged on specific drug exposures and their potential downstream consequences. One such area of heightened scrutiny involves the medication Ozempic, originally developed for metabolic regulation, and its association with gastrointestinal complications, including gastroparesis. This shift represents a natural progression from general health literacy to targeted risk awareness, particularly for individuals who have been prescribed this therapy.

Transitioning to Legal and Temporal Dimensions

The transition from broad health education to occupational exposure concern becomes particularly relevant when considering the legal and temporal dimensions of pharmaceutical liability. For those who have used Ozempic and subsequently developed gastroparesis, understanding the statute of limitations in jurisdictions such as Virginia is critical. This concern moves beyond general health information into the realm of personal injury law, where timely action is essential. The following discussion will address these legal parameters without venturing into mechanistic claims or citing external evidence, maintaining a neutral academic tone throughout.

Ozempic and Gastroparesis: Medical and Risk Considerations for Virginia Patients

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or, in severe cases, surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes. Its pharmacology includes slowing gastric emptying, which contributes to glycemic control by reducing postprandial glucose excursions. However, this mechanism also underlies a range of gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these trial data, the known effect of GLP-1 receptor agonists on gastric motility provides a mechanistic pathway linking Ozempic to delayed gastric emptying. The drug’s label does not include a specific warning for gastroparesis, though it does caution about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The adequacy of warnings regarding Ozempic and gastroparesis is a key consideration for affected patients. The label’s focus on common gastrointestinal symptoms like nausea and vomiting may not fully alert prescribers and patients to the risk of developing a chronic condition such as gastroparesis. For patients in Virginia who have developed gastroparesis after using Ozempic, attorney-related considerations include the statute of limitations for filing a product liability claim. In Virginia, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. The timeline between exposure to Ozempic and documented harm is critical. Patients may have used the drug for months or years before gastroparesis symptoms became severe enough to prompt medical evaluation and diagnosis. This latency period can complicate the determination of when the statute of limitations begins. Legal counsel can help assess whether the claim is timely and gather evidence such as medical records documenting the diagnosis and its temporal relationship to Ozempic use. Risk anchors for affected patients include the need to establish a causal link between Ozempic and gastroparesis, which may require expert testimony from gastroenterologists and pharmacologists. The absence of a specific warning on the label may support arguments that the manufacturer failed to adequately warn about this risk. Patients should also consider the potential for other contributing factors, such as pre-existing diabetes, which is itself a risk factor for gastroparesis. However, the temporal association and the known pharmacological effect of Ozempic on gastric emptying can strengthen a claim. In summary, Ozempic’s mechanism of slowing gastric emptying, combined with clinical trial data showing a high incidence of gastrointestinal adverse reactions, provides a plausible basis for a link to gastroparesis. Virginia patients who have developed this condition should be aware of the statute of limitations and seek legal advice promptly. The adequacy of warnings remains a central issue, as the label does not specifically address gastroparesis despite the drug’s known effects on gastric motility.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Virginia?

In Virginia, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For Ozempic-related gastroparesis, this means the clock starts when you knew or should have known that your gastroparesis was linked to Ozempic use. Given the latency period, it is crucial to consult an attorney promptly to determine if your claim is timely.

Does Ozempic's label warn about gastroparesis?

No, the current label for Ozempic does not include a specific warning for gastroparesis. It does caution about serious hypersensitivity reactions such as anaphylaxis and angioedema, and lists common gastrointestinal side effects like nausea and vomiting. The absence of a specific gastroparesis warning may be a key factor in product liability claims, as it could indicate that the manufacturer failed to adequately warn about this risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.